Bad news for Eli Lilly (NYSE: LLY) stock dragged down shares of rival companies in the market for GLP-1 diet drugs on Tuesday ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

The deal expands a deal to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using ...

Denmark's Novo Nordisk on Wednesday announced an expansion of its collaboration with Valo Health to discover and develop ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...